Dimerix logo

DXB - Dimerix Share Price

A$0.14 -0.0  -3.5%

Last Trade - 4:59am

Sector
Healthcare
Size
Micro Cap
Market Cap £12.0m
Enterprise Value £10.1m
Revenue £9.44k
Position in Universe 1120th / 1826
Bullish
Bearish
Unlock DXB Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

DXB Revenue Unlock DXB Revenue

Net Income

DXB Net Income Unlock DXB Revenue

Normalised EPS

DXB Normalised EPS Unlock DXB Revenue

PE Ratio Range

DXB PE Ratio Range Unlock DXB Revenue

Dividend Yield Range

DXB Dividend Yield Range Unlock DXB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
DXB EPS Forecasts Unlock DXB Revenue
Profile Summary

Dimerix Limited, formerly Sun Biomedical Limited, is clinical-stage biotechnology company, which is focused on developing therapeutics discovered using its drug development platform, Receptor-Heteromer Investigation Technology (HIT). The Company's principal activity is the development of its DMX-200 clinical asset for the treatment of chronic kidney disease and the commercialization of its underlying drug discovery technology. The Company's business segments are the development of occupational drug testing devices and new therapeutic agents in Australia, and clinical-stage drug discovery and development in Australia. Its DMX-200 is a combination of two existing drugs: irbesartan and propagermanium. DMX-200 is in Phase II clinical trials. It also has additional programs in its pipeline, including therapeutic candidates for treatment of Nonalcoholic Steatohepatitis (NASH) (fatty liver disease), Ocular diseases, Cancer fatigue and Multiple sclerosis.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated May 13, 1975
Public Since July 5, 1989
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 158,799,437
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address 425 Smith Street, MELBOURNE, 3065, Australia
Web http://dimerix.com/
Phone +61 3 00813321
Contact ()
Auditors Stantons International
DXB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for DXB
Upcoming Events for DXB
Similar to DXB
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.